4.6 Review

Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer

Journal

CANCERS
Volume 14, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14071656

Keywords

non-small cell lung cancer; chemotherapy; radiotherapy; chemoradiotherapy; concomitant; locally advanced; NSCLC; multimodality; immunotherapy; targeted therapy; surgery

Categories

Ask authors/readers for more resources

This review summarizes the latest data on multimodality treatment options for stage IIIA-N2 locally advanced non-small cell lung cancer (NSCLC), including chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. The role of surgery is being redefined, and surgical resection after induction immunotherapy or targeted therapy has shown promising short-term results.
Simple Summary Multimodality therapy for locally advanced non-small cell lung cancer (NSCLC) is a complex and controversial issue, especially regarding optimal treatment regimens for patients with ipsilateral positive mediastinal nodes (N2 disease). Is the landscape in this hotly debated stage changing the role for surgery as immunotherapy and targeted therapies are being investigated and implemented? A review on multimodality therapeutic options for stage IIIA-N2 NSCLC is presented. For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available